ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drug Metabolism and Transport
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1621959
Population Pharmacokinetics of Teicoplanin and Dosage Optimization in Sepsis Patients based on Continuous Renal Replacement Therapy
Provisionally accepted
- 1Department of Intensive Care Unit, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, Guizhou Province 550000, China
- 2Department of Pathogenic microorganism, Bijie Medical College, Bijie, Guizhou Province 551700, China
- 3Department of Intensive Care Unit, Kaiyang County People's Hospital, Guiyang, Guizhou Province 550300, China
- 4Department of Pharmacy, Huadu District People's Hospital of Guangzhou, Guangzhou 501800, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: It is well known that pharmacokinetics (PK) of drugs is significantly altered in sepsis patients receiving continuous renal replacement therapy (CRRT). However, clinical studies investigating the PK of drugs administered during CRRT are limited, and appropriate dosing regimens have not yet to be definitively established. The study aimed to develop a population PK model for teicoplanin, explore significant covariates regarding to teicoplanin PK, and propose optimal dosage strategies for sepsis patients.Methods: Eighty-six sepsis patients were included and plasma samples from all patients were analyzed. PK analysis was conducted on samples from 86 sepsis patients, followed by population PK analysis and simulations to ascertain the probability of target attainment (PTA).Results: Teicoplanin was well characterized by a one-compartment PK model with firstorder elimination. The presence of CRRT was associated with a lower volume of distribution (V), and gender was associated with a higher V. When MIC was set at 1 mg/L, a loading dose of 800 mg (q12h) followed by a maintenance dose of 600 mg(q24h) was necessary for male sepsis patients without CRRT, and a loading dose of 800 mg (q12h) followed by a maintenance dose of 800 mg (q24h) for male sepsis patients receiving CRRT. Female patients with sepsis required a loading dose of 1000 mg q12h followed by a maintenance dose of 1000 mg q24h.Teicoplanin therapy in sepsis patients undergoing CRRT necessitates individualized dosing. A PK model-based teicoplanin dosing regimen for sepsis patients with CRRT was proposed, whereas prospective clinical study is required to validate.
Keywords: Teicoplanin, pharmacokinetics, dosage optimization, Sepsis, continuous renal replacement therapy
Received: 02 May 2025; Accepted: 10 Jun 2025.
Copyright: © 2025 Sun, Jian, Zhou, Hong, Yang, Zheng, Wang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Siyi Wang, Department of Pharmacy, Huadu District People's Hospital of Guangzhou, Guangzhou 501800, China
Maojun Zhao, Department of Intensive Care Unit, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, Guizhou Province 550000, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.